Purpose This study evaluated pharmacokinetics (PK) and safety profiles of single agent arsenic trioxide (ATO, As O ) 2 3 administrated as continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Patients and methods Patients received 0.16 mg/kg ATO per day. ATO was given for 40 min infusion on the first day fol- lowed by 18–20 h daily at a very slow rate with infusion speed of 8 drips/min. During the first week, plasma samples were collected immediately before next administration on each day, and 0.5, 1, 2, 4, 8, 12 h after administration, at the end of III infusion (18 h) on day 7. Total arsenic was determined by ICPMS. Arsenic species, arsenious acid (As ) and its metabolites, V V monomethylarsonic acid (MMA ) and dimethylarsinic acid (DMA ), were quantified by UHPLC-ICPMS. Safety assessment and PK analysis was conducted. Results Hyperleukocytosis occurred in two patients and no severe toxicity was observed. Total arsenic gradually accumu- lated from 15.84 to 34.12 ng/mL during the first week of therapy. MMA /iAs increased and remained stable at value about V V III 0.6 after day 4, while DMA /MMA declined under 2 after day 4. Compared with 2 h infusion, clearance (CL) of As was
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: May 29, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera